11 results about "Acetazolamide" patented technology

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

The application discloses a molecular marker of citrus full mite resistance to ethyl acetazolamide and application thereof, and the molecular marker is SNP mutation A269G and / or T270A of succinate dehydrogenase SDHD subunit of the citrus full mite. A detection method of the molecular marker of the citrus full mite resistance to ethyl acetazolamide is also disclosed, total DNA of the citrus full mite to be detected is extracted, PCR amplification is carried out with the total DNA as a template, a succinate dehydrogenase SDHD subunit gene fragment containing a mutation region is obtained, and the obtained gene fragment is subjected to sequence comparison with the molecular marker, so that the resistance of the citrus full mite to be detected to ethyl acetazolamide can be judged. The molecular marker and the detection method can simultaneously detect a large number of samples, can quickly and effectively detect whether the resistance SNP molecular marker and the mutation proportion exist in a field population of the citrus full mite, and can evaluate the mutation frequency of the corresponding site in a certain geographical population.

The present invention relates to a culture method for improving cell resistance to high pCO2 environmental pressure, which specifically comprises the following steps: a) inoculating cells and culturing at 36-37°C; b) culturing cells at a temperature of 8-30×10 6 cells / ml, lowering the culture temperature to 30-32°C, introducing CO2 to lower the pH from a first pH in the range of 7.00±0.20 to a pH in the range of 6.7-6.90, wherein the first pH is greater than the second pH, and maintaining the pH until the cells are harvested; c) in step b), simultaneously with lowering the temperature, adding acetazolamide at a concentration of 50 μM-150 μM; and d) harvesting the cells and collecting the antibody protein product. Also provided are alternative methods for increasing the CO2 partial pressure in step b), and the corresponding use of acetazolamide for reducing lactic acid accumulation in cell culture and reducing the pentamethylene glycol ratio of the antibody protein produced after cell culture.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to phenyl sulfanilamide para-triazole derivatives, a preparation method and application of the phenyl sulfanilamide para-triazole derivatives in resisting carbonic anhydrase. The structural general formula of the derivative is as shown in formula I, the invention provides a brand-new phenyl sulfanilamide para-triazole derivative and pharmaceutically acceptable salt, the inhibition activity of the derivative on human carbonic anhydrase is obviously superior to that of traditional inhibitors acetazolamide and methazolamide, and the derivative has selective binding capacity on different human carbonic anhydrase subtypes and has the potential to be developed into a novel carbonic anhydrase inhibition drug.

A method for quantitative measurement of cerebral vascular reactivity (CVR) combines sequential gas delivery with ΔR2*-based perfusion analysis. Sequential gas delivery imposes a first stepwise reoxygenation after a first hypoxic condition and a second stepwise reoxygenation after a second hypoxic condition. In one mode, the second hypoxic condition produces greater vasodilation than the first; in another mode both hypoxia levels are minimal and an independent vasoactive stimulus, such as hypercapnia or acetazolamide, is applied between reoxygenations. MRI gradient-echo imaging records the ΔR2* time course in a target voxel during each reoxygenation. Sigmoid fitting yields perfusion metrics including relative cerebral blood flow, relative cerebral blood volume and mean transit time. Comparison of the metrics derived from the two reoxygenations provides a numerical CVR value that can be reproduced across sessions and subjects.

The application provides a PET imaging agent targeting a CAIX receptor, a PET imaging agent labeling precursor and a preparation method and application thereof, and belongs to the field of radiopharmaceutical labeling, wherein the PET imaging agent precursor has a structure as shown in formula I, formula II or formula III. The PET imaging agent and the PET imaging agent labeling precursor have the advantages of simple preparation method, short preparation time, high radiochemical yield, good in-vivo and in-vitro stability, high specificity, high uptake and the like, and can accurately and stably detect and locate a tumor or an inflammation site. In addition, the PET imaging agent is a Ga-68 labeled targeting CAIX radioactive probe synthesized based on the chemical structure of acetazolamide, the application can realize qualitative diagnosis of CAIX in a tumor, and can provide reliable basis for accurate diagnosis and correct decision in the stages of clinical staging, treatment decision, efficacy monitoring and the like, and finally realizes precise diagnosis and treatment.

A method for the quantitative measurement of cerebral vascular reactivity (CVR) combines sequential gas delivery with ΔR2*-based perfusion analysis. The sequential gas delivery induces a first stepwise reoxygenation following an initial hypoxic state and a second stepwise reoxygenation following a second hypoxic state. In one mode, the second hypoxic state produces greater vasodilation than the first; in another mode, both hypoxia levels are minimal, and an independent vasoactive stimulus, such as hypercapnia or acetazolamide, is applied between reoxygenations. MRI gradient echo imaging records the ΔR2* time course in a target voxel during each reoxygenation. Sigmoid fitting provides perfusion metrics, including relative cerebral blood flow, relative cerebral blood volume, and mean transit time.The comparison of the measured values ​​derived from the two reoxygenations yields a numerical CVR value that is reproducible across sessions and subjects.

The application discloses a new medical use of procyanidin B2 as a carbonic anhydrase IV (CA4) inhibitor. The application first confirms, by surface plasmon resonance (SPR) technology, that procyanidin B2 has direct and specific in-vitro combination with CA4 protein, and the equilibrium dissociation constant KD value is 7.51 μM. The application further confirms, by molecular docking, that the binding energy is-8.4 kcal / mol, which is superior to traditional inhibitors such as acetazolamide. The application further confirms, by molecular dynamics simulation, that the complex has high stability. The application further confirms, by HK-2 cell experiments, that procyanidin B2 can directly down-regulate the background expression of CA4 protein and re-regulate the abnormally high expression of CA4 induced by Ang II. Animal reference examples prove that the acacia extract containing procyanidin B2 can effectively improve the pathological damage of the kidney of SHR rats, reduce collagen deposition, reduce inflammatory factors and restore the folate level by inhibiting CA4. The application provides a new candidate drug molecule for treating renal fibrosis, hypertensive nephropathy and other related diseases by targeting CA4, and has a wide clinical application prospect.

The present application relates to a kind of drug for treating Meniere's disease and its application, it includes active ingredient ebselen and acetazolamide, wherein the weight ratio of ebselen and acetazolamide is 8-12:1.The present application can effectively improve the treatment or relieve Meniere's disease by using acetazolamide and ebselen in a certain proportion, by synergism, especially, can simultaneously relieve the rotation caused by Meniere's disease, nystagmus and head left and right swing.

The invention provides a medicinal preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising acetazolamide or acetazolamide derivatives and a pH regulator in a mass ratio of (10-15): (2-6). According to the invention, the acetazolamide or the acetazolamide derivative and the pH regulator are selected to prepare the pharmaceutical preparation, so that the pharmaceutical preparation can be used for preoperative cerebrovascular reserve capacity detection of a patient to be subjected to cerebral blood circulation and reconstruction, and can also be used for completing cerebrovascular reserve capacity detection of the patient after cerebral blood circulation and reconstruction; cerebral hemodynamics changes of a patient in a resting state before medication and a load state after medication are detected through a medical imaging means, a cerebrovascular reserve power evaluation standard is established according to the change degree, preoperative or non-operative indications are formulated according to the evaluation standard, postoperative success and failure and a recovery state of the patient are evaluated, and a cerebral vascular reserve power evaluation result is obtained. And a basis is provided for further treatment scheme design.

The invention discloses a ruthenium acid salt pharmaceutical composition and a preparation method and application thereof, the ruthenium acid salt pharmaceutical composition comprises trans-[tetrachloro bis (1H-indazole) ruthenium (III) acid salt] and a medical nitrogen-containing heterocyclic compound, and the medical nitrogen-containing heterocyclic compound comprises metiradone and / or acetazolamide. The medical nitrogen-containing heterocyclic compound of metiradone and / or acetazolamide disclosed by the invention is combined with a trans-[tetrachloro bis (1H-indazole) ruthenium (III) acid salt] compound for use, so that tumor growth can be well inhibited, and the medical nitrogen-containing heterocyclic compound is high in safety, free of pungent smell and good in chemical stability.